Innovation & intellectual property · 12/02/2001Updated: 10/17/2026 · 1 min read
U.S. Patent Office Grants Third Interim Extension to Roboxetine Patent
Summary
The United States Patent and Trademark Office has issued a certificate for a third one-year interim extension of the term of U.S. Patent No. 4,229,449, which covers the medication Roboxetine Mesylate
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →